CGTLive’s Weekly Rewind – August 5, 2022

Article

Review top news and interview highlights from the week ending August 5, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Allogeneic Cell Therapy Trial to Initiate in Ovarian Cancer

Avenge Bio previously presented positive preclinical data at the ASGCT 2022 meeting.

2. Craig M. McDonald, MD, on Safety and Efficacy of DMD Cell Therapy

The principal investigator of the HOPE-2 trial discussed safety and efficacy of Capricor’s CAP-1002.

3. REGENXBIO's MPSII Gene Therapy Charts Course to Approval

The FDA will consider RGX-121's BLA in an accelerated approval pathway.

4. IND Cleared for Dual-Targeted CAR T Therapy for B-Cell Malignancies

UCART2022 is an allogeneic therapy that targets both CD20 and CD22.

5. IND Halted for T-Cell Malignancy Multiplex-Edited Cell Therapy

Beam Therapeutics submitted an IND for BEAM-201 in June 2022.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Related Content
Study Suggests β-Thalassemia Gene Therapy May Help Improve Growth in Pediatric Patients

Study Suggests β-Thalassemia Gene Therapy May Help Improve Growth in Pediatric Patients

Noah Stansfield
June 12th 2025
Article

The study included 3 boys and 6 girls who were treated with gene therapy for TDT at 5 to 16 years of age.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman
May 29th 2025
Podcast

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Deevyashali Parekh, MBBS, an internal medicine resident at SUNY Upstate Medical University Hospital

Deevyashali Parekh, MBBS, on Evaluating the Prevalence of Second Primary Malignancies After CAR-T

Deevyashali Parekh, MBBS;Noah Stansfield
June 12th 2025
Article

The internal medicine resident at SUNY Upstate Medical University Hospital discussed the implications of findings from a deidentified database of EMR data.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman
April 8th 2025
Podcast

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

Louise Rodino-Klapac, PhD, the executive vice president, chief scientific officer, and head of research and development at Sarepta Therapeutics

Sarepta Garners Platform Technology Designation for Limb-Girdle Muscular Dystrophy Gene Therapy Vector

Noah Stansfield
June 10th 2025
Article

The platform technology designation is a new designation established by the FDA.

Kristina Jordahl, PhD, a principal scientist at Bristol Myers Squibb

Kristina Jordahl, PhD, on Arlo-Cel's Potential to Destroy Multiple Myeloma Cells While Preserving Immune Function

Kristina Jordahl, PhD;Noah Stansfield
June 10th 2025
Article

The principal scientist at Bristol Myers Squibb discussed a biomarker analysis she presented at ASCO's 2025 meeting.

© 2025 MJH Life Sciences

All rights reserved.